T-CELL LYMPHOMA
Clinical trials for T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study tested a drug called brentuximab vedotin in 23 people with a type of T-cell lymphoma that had stopped responding to or returned after prior chemotherapy. The drug is designed to seek out and kill cancer cells that have a specific marker called CD30, even when levels of…
Matched conditions: T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Deepa Jagadeesh • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New hope for tough blood cancers: experimental drug PRT2527 enters human testing
Disease control CompletedThis early-stage study tested a new drug called PRT2527 in 86 people with blood cancers like lymphoma and leukemia that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug works, both alone and combined with other…
Matched conditions: T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New hope for rare skin cancer: targeted therapy shows promise in chinese patients
Disease control CompletedThis study tested a drug called brentuximab vedotin in 10 Chinese adults with a rare type of skin lymphoma (CD30-positive cutaneous T-cell lymphoma). The goal was to see if the drug could shrink or eliminate cancer spots and to check for long-term side effects. Participants recei…
Matched conditions: T-CELL LYMPHOMA
Phase: PHASE4 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
CRISPR-Engineered immune cells take on tough blood cancers
Disease control CompletedThis study tested a new treatment called CTX131 for adults with blood cancers that came back or didn't respond to other therapies. CTX131 uses CRISPR gene editing to create donor immune cells that target and attack cancer cells. The goal was to see if it's safe and works, but it'…
Matched conditions: T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC